A Study of Brexpiprazole in Patients With Major Depressive Disorder

Overview

The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of brexipiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder.

Full Title of Study: “A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial to Assess the Efficacy and Safety of Brexpiprazole as Adjunctive Therapy in Patients With Major Depressive Disorder”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: June 6, 2022

Interventions

  • Drug: Brexpiprazole
    • Tablets, Oral, once daily, 14 weeks
  • Drug: Placebo
    • Tablets, Oral, once daily, 14 weeks

Arms, Groups and Cohorts

  • Experimental: Brexpiprazole 1mg
    • Tablets, Oral, 1mg once daily, 14 weeks Other Name: REXULTI
  • Experimental: Brexpiprazole 2mg
    • Tablets, Oral, 2 mg once daily, 14 weeks Other Name: REXULTI
  • Placebo Comparator: Placebo
    • Tablets, Oral, once daily, 14 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Mean changes from baseline in Montgomery Åsberg Depression Rating Scale (MADRS) total scores at last visit of the double-blind period
    • Time Frame: Baseline and Week 14
    • The MADRS is a clinician-rated scale which evaluates the level of depression. The MADRS consists of 10 items assessing apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thought. Each item is scored from 0 to 6, with higher scores indicating worse condition.

Secondary Measures

  • The proportion of subjects who score 1 or 2 on the Clinical Global Impression-Improvement (CGI-I) scale at Week 14
    • Time Frame: Baseline and Week 14
    • The CGI-I Scale is a clinician-rated scale which assesses the total improvement of the patient’s condition compared to that at baseline. Scores range from 0 to 7:0 = Not assessed, 1= Very much improved, 2 = Much improved, 3= Minimally improved, 4= No change, 5= Minimally worse, 6= Much worse, 7= Very much worse. Higher scores indicate worse condition.

Participating in This Clinical Trial

Inclusion Criteria

  • Outpatients, or inpatients at the time of informed consent whose treatment status can be successfully shifted to outpatient status before enrollment in the antidepressant treatment period – Male and female patients ≥ 20 to < 65 years of age (at the time of informed consent) – Patients who have a level of comprehension sufficient to allow them to give written informed consent to all of the observation/examination/evaluation items specified in the protocol, and who can understand the contents of the trial – Patients with a DSM-5 classification-based diagnosis of "major depressive disorder, single episode" or "major depressive disorder, recurrent episode," and whose current episode has persisted for at least 8 weeks Exclusion Criteria:

  • Women who are pregnant or breastfeeding or who have positive pregnancy test (urine) results at screening – Sexually active male subjects or sexually active female subjects of childbearing potential, who will not agree to practice 2 different methods of birth control or to remain abstinent during the trial and for 30 days after the final IMP administration. For birth control, 2 of the following methods must be used: vasectomy, tubal ligation, vaginal diaphragm, intra-uterine contraceptive device (IUD), oral contraceptives, or condom with spermicide. – Patients with a treatment history showing that all antidepressants (including those not used for the current major depressive episode) cannot be tolerated – Patients with a history of electroconvulsive therapy – Patients with a diagnosis of any of the following diseases according to DSM-5 1. Neurocognitive disorders 2. Schizophrenia spectrum and other psychotic disorders 3. Bipolar and related disorders 4. Feeding and eating disorders 5. Obsessive-compulsive disorder 6. Panic disorder 7. Posttraumatic stress disorder

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 64 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Otsuka Pharmaceutical Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.